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abstract
Objective To develop and validate two new fracture risk 
algorithms (QFractureScores) for estimating the individual 
risk of osteoporotic fracture or hip fracture over 10 years.
Design Prospective open cohort study with routinely 
collected data from 357 general practices to develop the 
scores and from 178 practices to validate the scores.
Setting General practices in England and Wales.
Participants 1 183 663 women and 1 174 232 men aged 
30-85 in the derivation cohort, who contributed 7 898 208 
and 8 049 306 person years of observation, respectively. 
There were 24 350 incident diagnoses of osteoporotic 
fracture in women and 7934 in men, and 9302 incident 
diagnoses of hip fracture in women and 5424 in men.
Main outcome measures First (incident) diagnosis of 
osteoporotic fracture (vertebral, distal radius, or hip) and 
incident hip fracture recorded in general practice records.
Results Use of hormone replacement therapy (HRT), 
age, body mass index (BMI), smoking status, recorded 
alcohol use, parental history of osteoporosis, rheumatoid 
arthritis, cardiovascular disease, type 2 diabetes, asthma, 
tricyclic antidepressants, corticosteroids, history of 
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falls, menopausal symptoms, chronic liver disease, 
gastrointestinal malabsorption, and other endocrine 
disorders were significantly and independently associated 
with risk of osteoporotic fracture in women. Some variables 
were significantly associated with risk of osteoporotic 
fracture but not with risk of hip fracture. The predictors 
for men for osteoporotic and hip fracture were age, 
BMI, smoking status, recorded alcohol use, rheumatoid 
arthritis, cardiovascular disease, type 2 diabetes, asthma, 
tricyclic antidepressants, corticosteroids, history of falls, 
and liver disease. The hip fracture algorithm had the best 
performance among men and women. It explained 63.94% 
of the variation in women and 63.19% of the variation 
in men. The D statistic values for discrimination were 
highest for hip fracture in women (2.73) and men (2.68) 
and were over twice the magnitude of the corresponding 
values for osteoporotic fracture. The ROC statistics for hip 
fracture were also high: 0.89 in women and 0.86 for men 
versus 0.79 and 0.69, respectively, for the osteoporotic 
fracture outcome. The algorithms were well calibrated 
with predicted risks closely matching observed risks. The 
QFractureScore for hip fracture also had good performance 
for discrimination and calibration compared with the FRAX 
(fracture risk assessment) algorithm.
Conclusions These new algorithms can predict risk of 
fracture in primary care populations in the UK without 
laboratory measurements and are therefore suitable for use 
in both clinical settings and for self assessment (at www.
qfracture.org). QFractureScores could be used to identify 
patients at high risk of fracture who might benefit from 
interventions to reduce their risk.
IntroductIon
There is no universally accepted policy for screening 
for patients at risk of osteoporotic fracture. Some guide‑
lines,1‑4 but not all,5 recommend a targeted approach 
based on the 10 year absolute risk of major osteoporotic 
fracture. 
We developed and validated two new fracture clini‑
cal risk scores (QFractureScores) derived from a vali‑
dated clinical research database (www.qresearch.org). 
We incorporated traditional variables already included 
in the FRAX (fracture risk assessment) algorithm,6 
added additional variables, extended the age range, 
and included a more detailed categorisation of alcohol 
and smoking status. Our new algorithm is based on 
What Is already knoWn on thIs topIc
Osteoporotic fracture is a major cause of morbidity, and 
interventions exist that can help reduce risk of fracture
Several international guidelines suggest a targeted 
approach for identifying high risk patients likely to benefit 
from interventions based on a 10 year absolute fracture 
risk
Risk prediction algorithms tend to perform best when they 
are developed in the clinical setting in which they will be 
applied
What thIs study adds
These new risk prediction algorithms (QFractureScores) 
for osteoporotic fracture and hip fracture do not require 
laboratory measurement and so can be used in primary 
care or for individual self assessment
The new algorithms include additional variables and were 
developed in and could be used in large representative 
primary care populations
The validation statistics, especially for the hip fracture 
algorithm, suggest that the QFractureScores are likely to 
be effective at identifying patients at high risk of fracture 
within primary care in the UK and showed improved 
performance compared with FRAX
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variables that are readily available without the need for 
laboratory tests or clinical measurements. 
Methods
Study design and data source
We conducted a prospective cohort study of primary 
care patients from our database. This contains the 
health records of over 11 million patients registered 
from 574 general practices that use the Egton Medical 
Information System (EMIS) computer system. Practices 
and patients contained on the database are nationally 
representative for England and Wales. 
Practice selection—We included all QResearch practices 
in England and Wales that had been using their current 
EMIS system for at least a year. We randomly allocated 
two thirds of practices to the derivation dataset and the 
remaining third to the validation dataset.
Cohort selection—We identified an open cohort of 
patients aged 30‑85 at the study entry date, drawn from 
patients registered with eligible practices during the 15 
years between 1 January 1993 and 30 June 2008. See 
bmj.com. 
Primary outcomes
Our two primary outcomes were the first (incident) 
diagnosis of an osteoporotic fracture (hip, vertebral, or 
distal radius) as recorded on the general practice com‑
puter records and incident diagnosis of hip fracture.
Fracture risk factors
We examined 18 explanatory variables in our analysis, 
all of which are known or thought to affect fracture risk 
and are also likely to be recorded within the patients’ 
electronic records as part of routine clinical practice. 
See bmj.com.
Model derivation and development
We calculated crude incidence rates of osteoporotic 
fracture (hip, vertebral, or distal radius fracture) and hip 
fracture by age and sex in the derivation and validation 
cohorts. We used Cox’s proportional hazards models in 
the derivation dataset to estimate the coefficients and 
hazard ratios associated with each potential risk factor 
for the first ever recorded diagnosis of osteoporotic frac‑
ture and hip fracture for men and women separately. 
We compared models using the Akaike information 
criterion (AIC) and the Bayes information criterion 
(BIC). We used fractional polynomials to model non‑
linear risk relations with continuous variables where 
appropriate. We tested for interactions between differ‑
ent variables and included significant interactions when 
they improved the model fit.
After conducting a complete case analysis, we used 
multiple imputation to replace missing values for alco‑
hol, smoking status, and BMI, and used these values in 
our main analyses. We took the regression coefficients 
for each variable from the final model and used these 
as weights for the QFractureScores and derived  risk 
equations for 10 years’ follow‑up. In women we deter‑
mined the hazard ratios for fracture overall and for hip 
fracture by HRT use at baseline categorised by (unop‑
posed, cyclical, or continuous) oestrogen dose (high or 
low) and type of oestrogen (equine v non‑equine). These 
results were incorporated in the QFractureScores for 
women. We also used a time varying Cox regression 
analysis to examine the effects of duration of use of 
HRT and time since stopping HRT on risk of fracture 
in women. See bmj.com.
Validation of the QFractureScore
We tested the performances of the final models in the 
validation dataset. We calculated the 10 year estimated 
risk of sustaining a fracture or hip fracture for each 
patient in the validation dataset using multiple imputa‑
tion to replace missing values as in the derivation data‑
set. We calculated the mean predicted fracture risk and 
the observed fracture risk at 10 years and compared 
these by 10th of predicted risk. We calculated the D 
statistic, an R2 statistic, and calculated the area under 
the receiver operating characteristics (ROC) curve at 
10 years. 
Validation against FRAX (fracture risk assessment)
We compared the performance of the QFractureScore 
in predicting risk of hip fracture with the performance 
of the FRAX algorithm using the above validation 
statistics. FRAX predicts 10 year absolute risk of hip 
fracture and osteoporotic fracture.6 It is not currently in 
widespread use in primary care in the United Kingdom. 
We used the UK version of the score from the FRAX 
website (www.shef.ac.uk/FRAX/index.htm) and the 
version that does not incorporate bone mineral density 
to calculate the 10 year predicted risk of hip fracture for 
all patients aged 40‑85 in the validation dataset.
results
Description of the derivation and validation dataset
Overall, 535 practices in England and Wales met our 
inclusion criteria, of which 357 were randomly assigned 
to the derivation dataset and 178 to the validation 
dataset. In the derivation cohort there were 1 204 222 
women (1 187 354 men) aged 30‑85 at baseline, of 
whom 20 559 (13 122) had a recorded fracture before 
the start of the study and were therefore excluded, leav‑
ing 1 183 663 (1 174 232) free of fracture at baseline for 
analysis. In the validation cohort there were 653 789 
women (640 943 men) aged 30‑85 at baseline, of whom 
11 636 (7179) had a fracture before the start of the study 
and were therefore excluded, leaving 642 153 (633 764) 
free of fracture at baseline for analysis.
The baseline characteristics in the validation cohort 
were similar to those for the derivation cohort across all 
measures in both men and women. See bmj.com. Dur‑
ing the 7 898 208 person years of follow‑up for women 
in the derivation cohort 24 350 fractures were recorded 
(hip, vertebral, or distal radius), giving an overall inci‑
dence rate of 3.08 per 1000 person years (95% confi‑
dence interval 3.04 to 3.12). For men, there were 7934 
incident fractures arising from 8 049 306 person years, 
giving an incidence rate of 0.99 per 1000 person years 
(0.96 to 1.01). In women, 38.2% of the fractures were 
hip fractures, in men the corresponding figure was 
BMJ | 5 DECEMBER 2009 | VoluME 339       1293
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38.9%. Similar incidence rates were found in the valida‑
tion cohort. Incidence rates were higher in women than 
in men and rose steeply with age. See bmj.com.
Model development
The results of the multivariate final Cox regression 
analysis for osteoporotic fracture and hip fracture in 
men and women based on a complete case analysis and 
using multiply imputed data are shown on bmj.com. 
Risk factors for fracture in men—After adjustment for 
all other variables in the model, we found significant 
associations with overall risk of fracture and risk of hip 
fracture in men for age, BMI, smoking status, alcohol 
use, rheumatoid arthritis, cardiovascular disease, type 
2 diabetes, asthma, use of tricyclic antidepressants, his‑
tory of falls, liver disease, and use of corticosteriods. 
These variables were included in both final algorithms 
for men.
Risk factors for fracture in women—After adjustment for 
all other variables in the model, we found significant 
associations with overall fracture risk in women for use 
of HRT, smoking status, use of alcohol, parental history 
of osteoporosis, rheumatoid arthritis, cardiovascular 
disease, type 2 diabetes, asthma, tricyclic antidepres‑
sants, use of corticosteroids, history of falls, menopau‑
sal symptoms, chronic liver disease, gastrointestinal 
malabsorption, and other endocrine disorders. There 
were also significant associations with age and BMI 
with fractional polynomial terms. The final algorithms 
for osteoporotic fracture and hip fracture in women 
included all of these variables. 
Effect of hormone replacement therapy on fracture risk
Overall, 168 536 women (14.24% of 1 183 663) were 
prescribed HRT at baseline. We found significant 
associations between risk of fracture and some types of 
HRT. See bmj.com and also some significant associa‑
tions in the time varying analyses for duration of use of 
HRT and time since stopping HRT.
Validation of the QFractureScores
The table shows the discrimination statistics for the 
QFractureScores. There was close correspondence 
between predicted and observed 10 year risks within 
each 10th of predicted risk in the validation cohort. 
For example, in the top 10th of risk for osteoporotic 
fracture in women, the mean predicted 10 year risk of 
fracture was 12.9% and the observed risk was 13.0%. 
See bmj.com.
Validation of the fracture clinical risk score against FRAX
We calculated a hip fracture score using the FRAX 
algorithm for 454 499 women aged 40‑85 and 424 336 
men aged 40‑85 in the validation cohort. The D statistic 
for hip fracture for the FRAX algorithm was 2.26 (2.21 
to 2.30) for women and 2.22 (2.14 to 2.30) for men. 
The FRAX algorithm explained 54.83% (54.43% to 
55.12%) of the variation in women and 54.07% (52.10% 
to 53.65%) in men. The ROC value for the FRAX algo‑
rithm was 0.845 for women and 0.817 for men.
We recalculated the validation statistics for the QFrac‑
tureScores restricting the population to patients aged 
40‑85. The D statistic for hip fracture was 2.37 (2.32 
to 2.42) for women and 2.39 (2.30 to 2.48) for men. 
The QFractureScores explained 57.29% (57.18% to 
58.09%) of the variation in women and 57.67% (56.78% 
to 58.57%) in men (figure).
dIscussIon
Summary of main findings
A new risk prediction algorithm (the QFractureScore) 
for estimating the 10 year absolute risk of hip fracture 
in men and women shows some evidence of improved 
discrimination and calibration compared with the 
FRAX algorithm. Given that FRAX was developed 
in multiple selected cohorts from across the world, the 
marginally poorer performance is not unexpected.
Our new algorithms do not require any laboratory 
testing or clinical measurements. They can be imple‑
mented within clinical computer systems in primary 
care and used to stratify the practice population by 
risk on a continuing basis without the need for manual 
data entry. The QFractureScores could therefore act as 
a basis for a systematic population based programme 
to identify high risk patients for further assessment 
and support the implementation of evolving clinical 
Clinical examples for patients who would be reclassified with QRISK2 instead of NICE modified Framingham equation
Age 
(years) Ethnic group
Family 
history
Systolic 
blood 
pressure BMI
Cholesterol/
HDL ratio Smoker
Treated 
hypertension
Type 2 
diabetes*
Chronic 
kidney 
disease
Townsend 
score†
Framingham 
score 10 year 
risk (%)
QRISK2 10 year 
risk (%) (95% CI)
Men
65 Indian Yes 100 24.7 3.3  No  No  No  No 5 17 31.3 (30.9 to 31.7)
54 Bangladeshi No 142 27.0 4.2  No Yes  No  No 10 17 23.5 (22.8 to 24.1)
54 Black African No 150 21.0 7.3  No  No  No  No 4 23 9.0 (7.7 to 10.3)
55 Indian No 156 27.0 4.7  No  No  No  No −4 24 12.7 (12.2 to 13.2)
65 Caribbean No 146 29.1 5.4  No  No  No  No 4 26 14.8 (14.2 to 15.5)
42 White Yes 132 36.0 5.3 Yes Yes  No  No 11 17 35.2 (34.9 to 35.5)
Women
64 Indian No 130 23.1 5.3  No Yes  No  No 5 12 24.7 (24.4 to 25.0)
60 Bangladeshi No 132 36.0 4.3  No Yes  No  No 11 9 21.1 (20.6 to 21.6)
48 Pakistani Yes 140 33.2 4.5  No Yes  No  No 8 9 26.1 (25.7 to 26.4)
58 White No 154 34.0 3.4 Yes Yes  No  No 10 16 21.4 (21.3 to 21.5)
BMI=body mass index; HDL=high density lipoprotein cholesterol.
*NICE lipid modification guideline does not include diabetes so this is for illustrative purposes only.
†Interval score ranges between −6 (most affluent) and 11 (most deprived).
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 guidelines in the UK. At the level of the individual 
patient, the algorithms can be used for self assessment 
in a web based calculator (www.qfracture.org). 
Hormone replacement therapy and fracture risk
We have shown an overall protective effect of HRT with 
a decreased risk with unopposed oestrogen. The effect 
is more marked for vertebral, distal radial, and hip frac‑
tures combined rather than hip fracture alone, probably 
because of lower numbers of patients with hip fracture 
by individual type of HRT. Our findings are consistent 
with those from other studies.7‑9 The loss of the protective 
effect of HRT on risk of fracture after stopping treatment 
is consistent with some9 10 but not other studies.11
Validation
The QFractureScores have good discrimination and 
explain over 60% of the variation for hip fracture. The 
practices used for the validation use the same clinical 
computer system (EMIS) as those used to derive the 
algorithm. The EMIS system, however, is currently in 
use in 60% of UK general practices and so the QFrac‑
tureScores are at least likely to perform well for over 
half of the UK’s population. Validation using the THIN 
database is currently under way. 
Comparison with other risk prediction algorithms
Unlike FRAX, the QFractureScores can be used in 
younger patients and can be used to estimate risk at one, 
two, five, and 10 years rather than just 10 years. Our new 
algorithms use more detailed variables and we hypoth‑
esise that the QFractureScores will be better at estimating 
risk for the individual patient by taking account of more 
information regarding the patient’s history. 
One potential limitation of the QFractureScores com‑
pared with FRAX is that they don’t include measurement 
of bone mineral density, but that does mean the scores 
can be applied without the need for expensive tests to 
identify high risk patients. Another potential limitation is 
that they are more complex than FRAX and some might 
think it is more difficult to implement. The main use of 
the QFractureScores, however, is likely to be integrated 
into general practice clinical computer systems, as well 
as a web based calculator (at www.qfracture.org), where 
software can automatically extract the necessary vari‑
ables, perform the calculations, and present the results 
to the clinician and individuals as appropriate. Open 
source software is also available from www.qfracture.org 
to help ensure reliable implementation of QFracture. In 
contrast, the FRAX algorithm is not publically available 
for clinical or research use.
Our algorithms also improve on the recent algorithm 
based on the Women’s Health Initiative cohort12 as they 
are estimated over a longer period than five years and 
include additional variables, such as HRT and have 
improved validation statistics.
Methodological considerations
Generalisability and measurement of outcomes —One strength 
of our study is its prospective cohort design based on 
the analysis of a large representative population from 
a validated database. The analyses can be updated 
as population characteristics change and as statistical 
methods advance. Our study has good validity as our 
hazard ratios for risk of hip fracture were similar to 
those found in other studies. In particular, our analysis 
supports a dose‑response relation for current smokers 
with lower risks among former smokers. We also found 
no association between hip fracture and deprivation, 
which confirmed findings reported elsewhere.13
QFractureScore - men
Tenth of predicted risk
%
 ri
sk
0 5 10 0 5 10
0.5
2.5
5.0
7.5
10.0
Tenth of predicted risk
QFractureScore - women
FRAX - menFRAX - women
%
 ri
sk
0
2
4
6
8
Observed 10 year risk
Predicted 10 year risk
Predicted and observed risk of hip fracture with QFractureScore and FRAX
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Sources of bias and unmeasured confounding —Several 
variables are reported by patients, such as alcohol, 
smoking, and parental history of hip fracture and 
might be subject to information or reporting bias. 
As the QFractureScores are intended for use within 
general practice clinical computer systems, however, 
similar conditions will apply and so the variables 
incorporated in the algorithm have intrinsic face 
validity. The study population is representative and 
unlikely to be affected by selection bias, in contrast 
with purpose designed clinical cohorts or clinical tri‑
als.9 14 We did not have objective measurements of 
some factors that might affect fracture risk, such as 
physical activity, and we had insufficient numbers of 
events within each ethnic group to allow for analyses 
by ethnicity. This should, however, improve over time 
as recording rates for ethnicity improve on GP clinical 
computer systems.   
Missing data—We used multiple imputation to 
substitute missing values for alcohol use, BMI, or 
smoking status. For other variables we assumed that 
if there was no recorded value the patient did not 
have that  exposure, which might have led to some 
 misclassification.
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Unwise words: now that wasn’t very clever
When doing an oncology outpatient clinic, I wheeled 
into the clinic room to see a patient for follow‑up of his 
condition; I use a wheelchair after spinal injury many 
years ago resulted in permanent paralysis from the 
chest down. After we had made our introductions, The 
patient asked, “Why are you in a wheelchair?” 
Whenever my wheelchair is mentioned, I try to focus 
the attention back on the patient, rather than explaining 
my situation. On this occasion, however, I said, “I 
broke my back almost 20 years ago.” 
The usual, “Rugby? Car accident?” came back, and I 
answered, “No, on a skiing holiday.”
He then replied with, “Now that wasn’t very clever.” 
Taken aback by this comment, I didn’t really know 
how to respond. Did it even deserve an answer? I 
had to bite my lip, remembering that patient needs 
come first in terms of the outcome of a consultation. 
I indicated that the accident hadn’t been planned—
after all, it wouldn’t otherwise have been an 
accident—and quickly moved on to addressing how 
the patient was. 
This experience did, however, remind me that 
living with disability is not only physically tiring, time 
consuming, and financially costly, but that it is also 
mentally demanding. You can get unwanted comments, 
most often when people respond with a clichéd phrase 
blurted out in a reflex manner to fill a verbal void. 
Unwise words are rarely maliciously intended, and 
it is usually best to respond gracefully. Disability, by 
testing your physical and mental resilience, teaches you 
to focus on the important things in life—the value of 
independence and surrounding yourself with positive 
and considerate people. Another lesson, of course, is 
the importance of either choosing your words carefully 
or saying nothing at all.
Tom Wells specialty doctor in oncology, Gloucestershire Oncology Centre 
thomas.wells@glos.nhs.uk
Cite this as: BMJ 2009;339:b4530
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Salt intake, stroke, and cardiovascular disease:  
meta-analysis of prospective studies
Pasquale Strazzullo,1 Lanfranco D’Elia,1 Ngianga-Bakwin Kandala,2 Francesco P Cappuccio2
total number of participants, country, sex, age, recruit-
ment time, follow-up, outcome, assessment methods for 
exposure and outcome, number (rate) of events, and salt 
intake in different categories. The pooled relative risk of 
stroke or cardiovascular disease for higher versus lower 
salt intake referred to a weighted average difference in 
habitual salt intake of 85 mmol or 5 g of salt per day.
Primary outcomes
The primary outcomes were fatal and non-fatal strokes 
and fatal and non-fatal total cardiovascular disease 
events.
Main results and role of chance
Thirteen studies reported on 19 independent cohorts, 
which included 177 025 participants from six countries. 
Eleven studies recruited both men and women, while 
two studies recruited only men. Follow-up ranged from 
3.5 to 19 years. Four studies reported only strokes, three 
only cardiovascular disease, and six both. Salt intake 
was assessed by 24 hour dietary recall (n=4), food fre-
quency questionnaire (n=4), 24 hour urine excretion 
(n=5), and questionnaire (n=1). There were 5346 strokes 
and 5161 cardiovascular events. In pooled analyses, 
an 85 mmol (or 5 g/day) higher salt intake was associ-
ated with greater risk of stroke (relative risk 1.23, 95% 
confidence interval 1.06 to 1.43; P=0.007). There was 
also an association between higher salt intake and risk 
of cardiovascular disease (1.17, 1.02 to 1.34; P=0.02). 
The effect seemed to be dose dependent for stroke and 
increased with the duration of follow-up.
Bias, confounding, and other reasons for caution
There was no evidence of publication bias. Heterogene-
ity, detected for both stroke and cardiovascular disease, 
was explored with meta-regression, sensitivity, and sub-
group analyses.
study funding/potential competing interests
Supported, in part, by an EC Grant (FP7-
HEALTH-2007-201550). The publication does not 
necessarily represent the decisions or the stated policy 
of WHO and the designations employed and the pres-
entation of the material do not imply the expression of 
any opinion on the part of the WHO.
Study queStion Is there a causal relation between 
levels of salt intake and the incidence of stroke and total 
cardiovascular outcomes?
Summary anSwer High salt intake is associated 
with significantly greater risk of both stroke and total 
cardiovascular disease.
what iS known and what thiS paper addS The 
potential benefits of less dietary salt in the prevention 
of cardiovascular disease have been extrapolated from 
the observed reduction in blood pressure with lower 
salt intake. This meta-analysis shows a significant direct 
association between higher habitual salt intake and risk of 
stroke and cardiovascular disease.
selection criteria for studies
Search of Medline (1966-2008), Embase (from 1988), 
AMED (from 1985), CINAHL (from 1982) Psychinfo 
(from 1985), and the Cochrane Library with no lan-
guage restrictions. Manual search of references from 
recent reviews and relevant published original studies, 
and examination of reference lists. Studies had to be 
original articles published between January 1966 and 
December 2008, population based prospective stud-
ies, assess salt intake as baseline exposure, have either 
stroke or total cardiovascular disease as outcome, fol-
low-up participants for at least three years, study adults, 
and indication of the number of participants exposed 
and the rate or number of events in different catego-
ries of salt intake. We recorded publication reference, 
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POOLED RELATIVE RISK ESTIMATES OF INCIDENT STROKES
AND TOTAL CARDIOVASCULAR EVENTS ASSOCIATED WITH
DIFFERENCE IN SALT INTAKE OF ABOUT 85 MMOL (5 G OF SALT) A DAY
*Without outliers, based on sensitivity analysis
Incident strokes
14 cohorts, 154 282
participants, 5346 events
Incident total cardiovascular events
14 cohorts, 104 933
participants, 5161 events
12 cohorts*, 101 996
participants, 5044 events
Size of effect
1.23 (1.06 to 1.43), P=0.007
1.14 (0.99 to 1.32), P=0.07
1.17 (1.02 to 1.34), P=0.02
Heterogeneity
I2=61%, P=0.04
I2=80%, P<0.01
I2=80%, P<0.01
Publication
bias
P=0.26
P=0.39
P=0.16
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twice as high in the most deprived areas than in the 
least deprived (incidence rate ratio 1.94, 95% confi-
dence interval 1.62 to 2.32). Mortality rates per 1000 
very preterm births showed little variation across all 
deprivation fifths (1.02 (0.86 to 1.20) for most deprived 
fifth versus least deprived). For infants surviving to 
discharge, measures of length of stay and provision 
of ventilation and respiratory support were similar 
across all deprivation fifths. Of very preterm infants 
surviving to discharge, 69% stayed in hospital more 
than 28 days, 47% needed ventilation at some point 
during their stay, and 78% needed at least one days’ 
respiratory support.
Bias, confounding, and other reasons for caution
We had no access to individual level measures of dep-
rivation, which might show inequalities in survival, risk 
profiles, or provision of neonatal care not seen with 
area level measures. Obtaining individual data, how-
ever, is more time consuming and costly. Our methods 
using area level measures are relatively straightforward 
to undertake and allow constant monitoring of serv-
ices for health service planners. The use of length of 
stay and ventilation and respiratory support reflect the 
major components of inpatient provision of neona-
tal care but clearly do not represent a detailed cost 
analysis.
Generalisability to other populations
The results are likely to be generalisable within 
 England as the study area represents about an elev-
enth of births in England and has a similar depriva-
tion profile to England as a whole, with a slight excess 
of more deprived areas. These results might also be 
generalisable to countries with similar provision and 
access to neonatal care.
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The study was funded by NHS research and develop-
ment funds from healthcare commissioners in the Trent 
region and by Action Medical Research.
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Socioeconomic inequalities in survival and provision of neonatal 
care: population based study of very preterm infants
Lucy K Smith, Elizabeth S Draper, Bradley N Manktelow, David J Field
Study queStion Are there socioeconomic inequalities 
in the survival and provision of neonatal care among very 
preterm infants?
Summary anSwer After very preterm birth, survival rates 
and neonatal care are similar for infants from all areas.
what iS known and what thiS paper addS Areas of high 
deprivation have high rates of neonatal and infant mortality 
and very preterm birth. The higher burden of mortality and 
increased neonatal care costs for very preterm infants in 
deprived areas is probably because of higher incidence 
rates and not differences in their individual severity of 
condition.
Participants and setting
All infants born between 22+0 and 32+6 weeks’ gesta-
tion who were alive at the onset of labour and whose 
mothers lived in the former Trent health region of the 
United Kingdom.
design, size, and duration
This was a prospective cohort study of infants born 
between 1 January 1998 and 31 December 2007 and 
followed until discharge from neonatal care. Detailed 
data on the infants and the provision of neonatal care 
were combined with mortality data and socioeconomic 
data based on the UK IMD2004 deprivation score at 
super output area level.
Primary outcomes
We calculated survival to discharge from neonatal care 
per 1000 total births and per 1000 very preterm births. 
Provision of neonatal care for very preterm infants sur-
viving to discharge was assessed with length of stay, 
provision of ventilation, and respiratory support.
Main results and the role of chance
In the 10 year period there were 7402 very preterm 
singleton births. The incidence was nearly twice as 
high in the most deprived areas than in the least 
deprived. Consequently rates of mortality because of 
very preterm birth per 1000 total births were almost 
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INCIDENCE OF VERY PRETERM BIRTH AND RELATIVE RISK OF MORTALITY BEFORE DISCHARGE FROM
NEONATAL CARE BY DEPRIVATION FIFTH (95% CONFIDENCE INTERVALS) IN INFANTS ALIVE AT ONSET OF LABOUR
Incidence of very preterm birth  per 1000 births
No of deaths before discharge
Relative risk for mortality per 1000 total births
Relative risk for mortality per 1000 very preterm births
Least deprived
fifth (n=1026)
9.5 (8.9 to 10.1)
180
1
1
Most deprived
fifth (n=1957)
18.1 (17.3 to 18.9)
349
1.94 (1.62 to 2.32)
1.02 (0.86 to 1.20)
All
(n=7402)
13.7 (13.4 to 14.0)
1289
—
—
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The economy-wide impact of pandemic influenza on the uK: 
a computable general equilibrium modelling experiment
Richard D Smith,1 Marcus R Keogh-Brown,1 Tony Barnett,1 2 Joyce Tait3
design
A computable general equilibrium model of the 
UK economy was specified for various combina-
tions of mortality and morbidity from pandemic 
influenza, vaccine efficacy, school closures, and pro-
phylactic absenteeism based on published pandemic 
data.
source(s) of effectiveness
Vaccine efficacy is estimated from published stud-
ies of influenza vaccines, and estimation of the effi-
cacy of school closures to mitigate the disease are 
taken from modelling studies and other published 
sources.
data sources
Parameter assumptions (and their sources) are tabu-
lated in the paper. Disease estimates are taken from 
pandemic planning documents, assumptions about 
absenteeism from work in response to school clo-
sures are taken from published surveys, and mitiga-
tion impacts are estimated from published models. 
Published studies of social networking theory are 
used to estimate a transition point for prophylactic 
absenteeism.
results of sensitivity analysis
The unpredictability of influenza pandemics does 
not permit confidence intervals for sensitivity. 
Instead, we present scenarios with varying sever-
ity of disease to show the sensitivity of our results. 
Our results are sensitive in particular to changes in 
fatality rate. Closure of schools for 15 weeks rather 
than 4 weeks results in an increased impact of about 
2.5% of GDP. Our results are not very sensitive to 
changes in the efficacy of school closures to mitigate 
the pandemic.  
limitations
This work does not take into account consump-
tion effects from avoidance of public places and 
changes in shopping patterns. The strength of our 
findings depends on the underlying assumptions 
which, while based on published evidence where 
possible, are subject to the bias of surveys and the 
unpredictability of the disease and its resultant 
impact on policies and behavioural changes. There 
is also potential for wide variations in our social net-
working estimates when theory gives way to mid-
pandemic practice. 
study funding/potential competing interests
None declared.
Study queStion What is the potential economic impact of 
pandemic influenza, and associated palliative responses, 
in the United Kingdom?
Summary anSwer The economic impact of disease alone 
is small, but school closures could greatly increase this 
impact and widespread absence from work in an attempt to 
avoid infection could provoke large costs with few benefits. 
An effective vaccine could greatly reduce the economic 
costs of a pandemic.
what iS known and what thiS paper addS Government 
sanctioned school closure in response to a flu pandemic 
could have a substantial economic impact which may not 
be balanced by health benefits. Our model suggests that 
vaccines play the major role in mitigating the economic 
impact of a pandemic and also estimates the impact of fear-
induced behavioural change. 
Main results
Results are presented for low, medium, and high clini-
cal attack rate and low, high, and extreme case fatality 
rates, yielding nine disease scenarios. The costs related 
to illness alone are likely to range between 0.5% and 
1.0% of gross domestic product (GDP) (£8.4bn to 
£16.8bn) for low fatality scenarios, 3.3% and 4.3% 
(£55.5bn to £72.3bn) for high fatality scenarios, 
and larger still for an extreme pandemic. School clo-
sure increases the economic impact, particularly for 
mild pandemics. If there is widespread prophylactic 
absence from work, the economic impacts could be 
greatly increased with few health benefits. Vaccina-
tion (at 60% coverage) with a pre-pandemic vaccine 
could save 0.13-2.3% of GDP (£2.2bn-£38.6bn), while 
a single dose of matched vaccine could save 0.3-4.3% 
(£5.0bn-£72.3bn) and a double dose of matched vac-
cine could limit the overall economic impact to about 
1% of GDP for all disease scenarios.
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IMPACT OF PANDEMIC INFLUENZA ON GROSS DOMESTIC
PRODUCT BY VARIOUS DISEASE AND MITIGATION SCENARIOS
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